Sirolimus and intraoperative hyperthermic peritoneal chemoperfusion with mitomycin-C do not impair healing of bowel anastomoses

Transplant International

Volumn 21, Issue 6, 2008, Pages 554-563

  Wagner, Oliver J ^b   Inglin, Roman A ^b   Bisch Knaden, Sonja ^b   Mettler, Daniel ^b   Borner, Markus ^b   Candinas, Daniel ^b   Egger, Bernhard ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Anastomotic healing; Colon; Intraoperative hyperthermic peritoneal chemoperfusion; Mitomycin C; Pig; Sirolimus

Indexed keywords

BROXURIDINE; KI 67 ANTIGEN; MITOMYCIN C; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HISTOPATHOLOGY; HYPERTHERMIC THERAPY; IMMUNOHISTOCHEMISTRY; INTESTINE ANASTOMOSIS; INTESTINE FUNCTION; LOADING DRUG DOSE; NONHUMAN; PEROPERATIVE CARE; PRIORITY JOURNAL; SWINE; WOUND HEALING;

ANASTOMOSIS, SURGICAL; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL PROLIFERATION; DIGESTIVE SYSTEM NEOPLASMS; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL MUCOSA; INTESTINES; MITOMYCIN; MODELS, ANIMAL; PERFUSION; PERITONEAL CAVITY; PERITONEAL NEOPLASMS; SIROLIMUS; SUS SCROFA; WOUND HEALING;

EID: 42649137224     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2007.00635.x     Document Type: Article

References (46)

1. Adam R, McMaster P, O'Grady JG, et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl 2003 9 : 1231.
2. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000 342 : 605.
3. London NJ, Farmery SM, Will EJ, Davison AM, Lodge JP. Risk of neoplasia in renal transplant patients. Lancet 1995 346 : 403.
4. Adami J, Gabel H, Lindelof B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003 89 : 1221.
5. Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf 2000 23 : 101.
6. Kahan BD, Yakupoglu YK, Schoenberg L, et al. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 2005 80 : 749.
7. Helderman JH, Goral S. Gastrointestinal complications of transplant immunosuppression. J Am Soc Nephrol 2002 13 : 277.
8. Tyau ES, Prystowsky JB, Joehl RJ, Nahrwold DL. Acute diverticulitis. A complicated problem in the immunocompromised patient. Arch Surg 1991 126 : 855.
9. Wagner OJ, Egger B. Influential factors in anastomosis healing. Swiss Surg 2003 9 : 105.
10. Zeeh J, Inglin R, Baumann G, et al. Mycophenolate mofetil impairs healing of left-sided colon anastomoses. Transplantation 2001 71 : 1429.
11. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975 28 : 721.
12. Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 1975 28 : 727.
13. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003 35 : 7S.
14. Dean PG, Lund WJ, Larson TS, et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 2004 77 : 1555.
15. Fisher A, Seguel JM, de la Torre AN, et al. Effect of sirolimus on infection incidence in liver transplant recipients. Liver Transpl 2004 10 : 193.
16. Kuppahally S, Al Khaldi A, Weisshaar D, et al. Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am J Transplant 2006 6 : 986.
17. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000 88 : 358.
18. Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995 221 : 124.
19. Markman M. Intraperitoneal chemotherapy in the management of colon cancer. Semin Oncol 1999 26 : 536.
20. Sticca RP. Peritoneal carcinomatosis: a final frontier. Ann Surg Oncol 2003 10 : 484.
21. Elias D, Blot F, El Otmany A, et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 2001 92 : 71.
22. Glehen O, Cotte E, Schreiber V, Sayag-Beaujard AC, Vignal J, Gilly FN. Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg 2004 91 : 747.
23. Elias DM, Ouellet JF. Intraperitoneal chemohyperthermia: rationale, technique, indications, and results. Surg Oncol Clin N Am 2001 10 : 915.
24. de Roy van Zuidewijn DB, Hendriks T, Wobbes T, de Boer HH. Intraperitoneal cytostatics impair healing of experimental intestinal anastomoses. Br J Cancer 1991 63 : 937.
25. Makrin V, Lev-Chelouche D, Even SE, Paran H, Rabau M, Gutman M. Intraperitoneal heated chemotherapy affects healing of experimental colonic anastomosis: an animal study. J Surg Oncol 2005 89 : 18.
26. Beaujard AC, Glehen O, Caillot JL, et al. Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. Cancer 2000 88 : 2512.
27. Egger B, Inglin R, Zeeh J, Dirsch O, Huang Y, Buchler MW. Insulin-like growth factor I and truncated keratinocyte growth factor accelerate healing of left-sided colonic anastomoses. Br J Surg 2001 88 : 90.
28. Granger DK, Cromwell JW, Chen SC, et al. Prolongation of renal allograft survival in a large animal model by oral rapamycin monotherapy. Transplantation 1995 59 : 183.
29. Bestetti R, Theodoropoulos TA, Burdmann EA, Filho MA, Cordeiro JA, Villafanha D. Switch from calcineurin inhibitors to sirolimus-induced renal recovery in heart transplant recipients in the midterm follow-up. Transplantation 2006 81 : 692.
30. Egger B, Tolmos J, Procaccino F, et al. Keratinocyte growth factor promotes healing of left-sided colon anastomoses. Am J Surg 1998 176 : 18.
31. Wind J, Koopman AG, Berge Henegouwen MI, Slors JF, Gouma DJ, Bemelman WA. Laparoscopic reintervention for anastomotic leakage after primary laparoscopic colorectal surgery. Br J Surg 2007 94 : 1562.
32. Nair RV, Huang X, Shorthouse R, et al. Antiproliferative effect of rapamycin on growth factor-stimulated human adult lung fibroblasts in vitro may explain its superior efficacy for prevention and treatment of allograft obliterative airway disease in vivo. Transplant Proc 1997 29 : 614.
33. Troppmann C, Pierce JL, Gandhi MM, Gallay BJ, McVicar JP, Perez RV. Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study. Transplantation 2003 76 : 426.
34. Rogers CC, Hanaway M, Alloway RR, et al. Corticosteroid avoidance ameliorates lymphocele formation and wound healing complications associated with sirolimus therapy. Transplant Proc 2005 37 : 795.
35. Dunkelberg JC, Trotter JF, Wachs M, et al. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl 2003 9 : 463.
36. Gaber MW, Aziz AM, Shang X, et al. Changes in abdominal wounds following treatment with sirolimus and steroids in a rat model. Transplant Proc 2006 38 : 3331.
37. Grim SA, Slover CM, Sankary H, Oberholzer J, Benedetti E, Clark NM. Risk factors for wound healing complications in sirolimus-treated renal transplant recipients. Transplant Proc 2006 38 : 3520.
38. Puglisi RN, Strande L, Santos M, Schulte G, Hewitt CW, Whalen TV. Beneficial effects of cyclosporine and rapamycin in small bowel ischemic injury. J Surg Res 1996 65 : 115.
39. van der Vliet JA, Willems MC, de Man BM, Lomme RM, Hendriks T. Everolimus interferes with healing of experimental intestinal anastomoses. Transplantation 2006 82 : 1477.
40. Mahalati K, Kahan BD. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 2001 40 : 573.
41. Kovarik JM, Kahan BD, Kaplan B, et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther 2001 69 : 48.
42. Kahan BD, Napoli KL, Kelly PA, et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin Transplant 2000 14 : 97.
43. Kovarik JM, Tedesco H, Pascual J, et al. Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation. Ther Drug Monit 2004 26 : 499.
44. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 2006 66 : 5527.
45. Jacquet P, Stephens AD, Averbach AM, et al. Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer 1996 77 : 2622.
46. Shen P, Levine EA, Hall J, et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg 2003 138 : 26.